Pauleatha Diggs

Pauleatha Diggs

Auto-generated profile, based on publicly available information

Pauleatha Diggs

Department of Dermatology Vanderbilt University Medical Center Nashville TN USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
JCJ. Nicholas Cochran
J. Nicholas Cochran
PDPauleatha V. Diggs
Pauleatha V. Diggs
NNN. Miranda Nebane
N. Miranda Nebane
LRLynn Rasmussen
Lynn Rasmussen
EWE. Lucile White
E. Lucile White
ERErik D. Roberson
Erik D. Roberson
Alzheimer disease (AD) is the most common neurodegenerative disease, and with Americans’ increasing longevity, it is becoming an epidemic. There are currently no effective treatments for this disorder. Abnormalities of Tau track more closely with cognitive decline than the most studied therapeutic target in AD, amyloid-β, but the optimal strategy for targeting Tau has not yet been identified. On the basis of considerable preclinical data from AD models, we hypothesize that interactions between Tau and the Src-family tyrosine kinase, Fyn, are pathogenic in AD. Genetically reducing either Tau or Fyn is protective in AD mouse models, and a dominant negative fragment of Tau that alters Fyn localization is also protective. Here, we describe a new AlphaScreen assay and a live-cell bioluminescence resonance energy transfer (BRET) assay using a novel BRET pair for quantifying the Tau–Fyn interaction. We used these assays to map the binding site on Tau for Fyn to the fifth and sixth PXXP motifs to show that AD-associated phosphorylation at microtubule affinity regulating kinase sites increases the affinity of the Tau–Fyn interaction and to identify Tau–Fyn interaction inhibitors by high-throughput screening. This screen has identified a variety of chemically tractable hits, suggesting that the Tau–Fyn interaction may represent a good drug target for AD.

1 March 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
BEBrandon I. Esianor
Brandon I. Esianor
ZJZi Yang Jiang
Zi Yang Jiang
PDPauleatha Diggs
Pauleatha Diggs
SYSancak Yuksel
Sancak Yuksel
SRSoham Roy
Soham Roy
ZHZhen Huang
Zhen Huang

31 January 2022 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
SKSharon Kam
Sharon Kam
SASantiago Angaramo
Santiago Angaramo
JAJacqueline Antoun
Jacqueline Antoun
MBManasa R Bhatta
Manasa R Bhatta
PBPauleatha Diggs Bonds
Pauleatha Diggs Bonds
CHChase D Hendrickson
Chase D Hendrickson
Background Annual albuminuria screening detects the early stages of nephropathy in individuals with diabetes. Because early detection of albuminuria allows for interventions that lower the risk of developing chronic kidney disease, guidelines recommend annual testing for all individuals with type 2 diabetes mellitus and for those with type 1 diabetes for at least 5 years. However, at the Eskind Diabetes Clinic at the Vanderbilt University Medical Center, testing occurred less frequently than desired. Methods A quality improvement team first analysed the clinic’s processes, identifying the lack of a systematic approach to testing as the likely cause for the low rate. The team then implemented two successive interventions in a pilot of patients seen by nurse practitioners in the clinic. In the first intervention, staff used a dashboard within the electronic health record while triaging each patient, pending an albuminuria order if testing had not been done within the past year. In the second intervention, clinic leadership sent daily reminders to the triage staff. A statistical process control chart tracked monthly testing rates. Results After 6 months, annual albuminuria testing increased from a baseline of 69% to 82%, with multiple special-cause signals in the control chart. Conclusions This project demonstrates that a series of simple interventions can significantly impact annual albuminuria testing. This project’s success likely hinged on using an existing workflow to systematically determine if a patient was due for testing and prompting the provider to sign a pended order for an albuminuria test. Other diabetes/endocrinology and primary care clinics can likely implement a similar process and so improve testing rates in other settings. When coupled with appropriate interventions to reduce the development of chronic kidney disease, such interventions would improve patient outcomes, in addition to better adhering to an established quality metric.

1 January 2020 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
MVMatthew T. Villaume
Matthew T. Villaume
DPDilan Patel
Dilan Patel
CLChristine Lopez
Christine Lopez
VPVivek Patel
Vivek Patel
PDPauleatha Diggs
Pauleatha Diggs
DMDavid Morgan
David Morgan
Dural Marginal Zone Lymphoma in a Patient With a Hepatitis C Virus Infection

1 November 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
PBPauleatha Diggs Bonds
Pauleatha Diggs Bonds
JHJoyce Huang
Joyce Huang
JIJacqueline Ike
Jacqueline Ike
EMEric Mukherjee
Eric Mukherjee
LPLynn Petukhova
Lynn Petukhova
LWLee Wheless
Lee Wheless

1 June 2021 in Otolaryngology Case Reports
Verified
Journal Article
Open access
PDPauleatha Diggs
Pauleatha Diggs
BEBrandon I. Esianor
Brandon I. Esianor
DSDaniel Schuster
Daniel Schuster